Lipodystrophy and its two components lipo-accumulation and lipoatropy are very common
among individuals with HIV infection on treatment, especially among those who started …

Body composition alterations are common in HIV infection and include AIDS wasting and
lipodystrophy. Both are associated with metabolic alterations, including hypertriglyceridemia …

Multiple complex strategies will need to be utilized in these patients to treat the different
features seen in lipodystrophy in order to reduce their long-term cardiovascular risk. Further …

HIV‐associated lipodystrophy syndrome (HALS) is characterized by body fat redistribution
as a consequence of the antiretroviral therapy (ART) introduction, associated with an …

Background. At present, no uniform definition of human immunodeficiency virus (HIV)–
associated lipoatrophy exists. The risk factors for fat atrophy (FA) and central fat deposition …

The objective of this study was to evaluate how much limb fat is needed to be lost for
lipoatrophy to become clinically evident. Antiretroviral drug-naive patients from a …

Approximately 50% of patients on highly active antiretroviral therapy (HAART) develop
lipodystrophy with central and visceral fat accumulation and/or facial and limb atrophy …

This study provides population-based estimates of the incidence of constituent symptoms
associated with HIV-related lipodystrophy syndrome. Possible predictors of symptomatology …

Background HIV disease itself is associated with increased healthcare utilization and
healthcare expenditures. HIV-infected persons with lipodystrophy have been shown to have …

HIV lipodystrophy is characterized by peripheral, subcutaneous lipoatrophy in the face,
arms, legs, and buttocks and central fat accumulation in the neck, breasts, and abdomen …